Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Articles and issues > Author index
Search
Ji Han Jung 2 Articles
Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer
Hong Sik Park, Uiju Cho, So Young Im, Chang Young Yoo, Ji Han Jung, Young Jin Suh, Hyun Joo Choi
J Pathol Transl Med. 2019;53(2):75-85.   Published online November 14, 2018
DOI: https://doi.org/10.4132/jptm.2018.10.11
  • 6,457 View
  • 178 Download
  • 24 Web of Science
  • 28 Crossref
AbstractAbstract PDF
Background
Human leukocyte antigen class I (HLA-I) molecules play important roles in regulating immune responses. Loss or reduction of HLA-I expression has been shown to be associated with prognosis in several cancers. Regulatory T-cells (Tregs) also play critical functions in immune response regulation. Evaluation of HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast cancer have not been well studied, and its relationship with Tregs remains unclear.
Methods
We evaluated HLA-I expression and Treg infiltration by immunohistochemistry in 465 surgically resected breast cancer samples. We examined the correlation between HLA-I expression and Treg infiltration and clinicopathologic characteristics and survival analyses were performed.
Results
Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). Univariate survival analysis revealed that loss of HLA-I expression was significantly associated with worse disease-specific survival (DSS) (p = .029). HLA-I was not an independent prognostic factor in the entire patient group, but it was an adverse independent prognostic factor for DSS in patients with advanced disease (stage II–IV) (p = .031). Treg numbers were significantly higher in the intratumoral stroma of HLA-I–positive tumors than in HLA-I–negative tumors (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). However, Tregs were not an independent prognostic factor in our cohort.
Conclusions
Our findings suggest that the loss of HLA-I expression is associated with poor prognosis in breast cancer patients, highlighting the role of HLA-I alterations in immune evasion mechanisms of breast cancer. HLA-I could be a promising marker that enables the application of more effective and precise immunotherapies for patients with advanced breast cancer.

Citations

Citations to this article as recorded by  
  • Comment on “Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta‑Analysis”
    Wei Han, Li-zhou Shi, Yu-wei Zhang, Hao-nan Wang
    Molecular Diagnosis & Therapy.2024; 28(2): 237.     CrossRef
  • Immunotherapy resistance in solid tumors: mechanisms and potential solutions
    Daniel S. Lefler, Steven A. Manobianco, Babar Bashir
    Cancer Biology & Therapy.2024;[Epub]     CrossRef
  • Assessment of cancer cell‐expressed HLA class I molecules and their immunopathological implications
    Terufumi Kubo, Shiori Asano, Kenta Sasaki, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Toshihiko Torigoe
    HLA.2024;[Epub]     CrossRef
  • Cancer Immunology: Immune Escape of Tumors—Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies
    Yuan Wang, Simon Jasinski-Bergner, Claudia Wickenhauser, Barbara Seliger
    Advances in Anatomic Pathology.2023; 30(3): 148.     CrossRef
  • In Silico Pipeline to Identify Tumor-Specific Antigens for Cancer Immunotherapy Using Exome Sequencing Data
    Diego Morazán-Fernández, Javier Mora, Jose Arturo Molina-Mora
    Phenomics.2023; 3(2): 130.     CrossRef
  • HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
    Ning Jiang, Yue Yu, Dawei Wu, Shuhang Wang, Yuan Fang, Huilei Miao, Peiwen Ma, Huiyao Huang, Min Zhang, Yu Zhang, Yu Tang, Ning Li
    Journal of Cancer Research and Clinical Oncology.2023; 149(2): 737.     CrossRef
  • Relationship between Systemic Inflammatory Markers, GLUT1 Expression, and Maximum 18F-Fluorodeoxyglucose Uptake in Non-Small Cell Lung Carcinoma and Their Prognostic Significance
    Sonya Youngju Park, Deog-Gon Cho, Byoung-Yong Shim, Uiju Cho
    Diagnostics.2023; 13(6): 1013.     CrossRef
  • Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis
    Weiqiang Qiao, Zhiqiang Jia, Wanying Guo, Qipeng Liu, Xiao Guo, Miao Deng
    Molecular Diagnosis & Therapy.2023; 27(5): 573.     CrossRef
  • Challenges and solutions for therapeuticTCR‐based agents
    Manish Malviya, Zita E. H. Aretz, Zaki Molvi, Jayop Lee, Stephanie Pierre, Patrick Wallisch, Tao Dao, David A. Scheinberg
    Immunological Reviews.2023; 320(1): 58.     CrossRef
  • Molecular mechanisms of impaired antigenic presentation as a cause of tumor escape from immune surveillance
    A.A. Korotaeva, A.A. Borunova, A.Yu. Kuzevanova, T.N. Zabotina, A.A. Alimov
    Arkhiv patologii.2023; 85(6): 76.     CrossRef
  • Immune Escape Mechanism of Cancer
    Ayse Caner
    Current Molecular Biology Reports.2023; 10(1): 9.     CrossRef
  • Upregulation of MHC I Antigen Processing Machinery Gene Expression in Breast Cancer Cells by Trichostatin A
    A. H. Murtadha, N. A. Sharudin, I. I. M. Azahar, A. T. Che Has, N. F. Mokhtar
    Molecular Biology.2023; 57(6): 1212.     CrossRef
  • Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors
    Ananthan Sadagopan, Theodoros Michelakos, Gabriella Boyiadzis, Cristina Ferrone, Soldano Ferrone
    JAMA Oncology.2022; 8(3): 462.     CrossRef
  • Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response
    Brandie C. Taylor, Justin M. Balko
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives
    Ioannis A. Vathiotis, Ioannis Trontzas, Niki Gavrielatou, Georgia Gomatou, Nikolaos K. Syrigos, Elias A. Kotteas
    Clinical Breast Cancer.2022; 22(7): 642.     CrossRef
  • Aberrant synaptophysin expression in classic Hodgkin lymphoma
    Soyoung Im, Jeong-A. Kim, Gyeongsin Park, Uiju Cho
    Diagnostic Pathology.2022;[Epub]     CrossRef
  • Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer
    Song-Hee Han, Milim Kim, Yul Ri Chung, Ji Won Woo, Hye Yeon Choi, So Yeon Park
    Scientific Reports.2022;[Epub]     CrossRef
  • Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
    Yuan Wei, Xiao Xiao, Xiang-Ming Lao, Limin Zheng, Dong-Ming Kuang
    Cellular and Molecular Life Sciences.2021; 78(3): 867.     CrossRef
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
    Leisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, Mary L Disis, Margaret E Gatti-Mays, Alice Y Ho, Kevin Kalinsky, Heather L McArthur, Elizabeth A Mittendorf, Rita Nanda, David B Page, Hope S Rugo, Krista M Rubin, Hatem Soliman, Patricia A Spears, Sara
    Journal for ImmunoTherapy of Cancer.2021; 9(8): e002597.     CrossRef
  • Resistance mechanisms to checkpoint inhibitors
    Sarah A Weiss, Mario Sznol
    Current Opinion in Immunology.2021; 69: 47.     CrossRef
  • The Immunology of Hormone Receptor Positive Breast Cancer
    Jonathan Goldberg, Ricardo G. Pastorello, Tuulia Vallius, Janae Davis, Yvonne Xiaoyong Cui, Judith Agudo, Adrienne G. Waks, Tanya Keenan, Sandra S. McAllister, Sara M. Tolaney, Elizabeth A. Mittendorf, Jennifer L. Guerriero
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • B4GALNT2 Gene Promotes Proliferation, and Invasiveness and Migration Abilities of Model Triple Negative Breast Cancer (TNBC) Cells by Interacting With HLA-B Protein
    Pu Yu, Lili Zhu, Kang Cui, Yabing Du, Chaojie Zhang, Wang Ma, Jia Guo
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
    Nina Radosevic-Robin, Pier Selenica, Yingjie Zhu, Helen H. Won, Michael F. Berger, Lorenzo Ferrando, Emiliano Cocco, Maud Privat, Flora Ponelle-Chachuat, Catherine Abrial, Jean-Marc Nabholtz, Frederique Penault-Llorca, Jorge S. Reis-Filho, Maurizio Scaltr
    npj Breast Cancer.2021;[Epub]     CrossRef
  • Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
    Liam Masterson, James Howard, Jazmina Gonzalez‐Cruz, Christopher Jackson, Catherine Barnett, Lewis Overton, Howard Liu, Rahul Ladwa, Fiona Simpson, Margie McGrath, Ben Wallwork, Terry Jones, Christian Ottensmeier, Melvin L.K. Chua, Chris Perry, Rajiv Khan
    International Journal of Cancer.2020; 146(8): 2305.     CrossRef
  • Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers
    Julia Y. Tsang, Chun-Sing Ho, Yun-Bi Ni, Yan Shao, Ivan K. Poon, Siu-Ki Chan, Sai-Yin Cheung, Ka-Ho Shea, Monalyn Marabi, Gary M. Tse
    Cancer Immunology, Immunotherapy.2020; 69(5): 799.     CrossRef
  • Breast cancer patients overall survival depends on a combination of the polymorphisms of tumor necrosis factor gene and HLA-haplotypes
    T.F. Malivanova, E.V. Alferova, A.S. Ostashkin, T.A. Astrelina, N.N. Mazurenko
    Molecular Genetics Microbiology and Virology (Russian version).2020; 38(1): 40.     CrossRef
  • The Overall Survival of Breast Cancer Patients Depends on a Combination of Polymorphisms of Tumor Necrosis Factor Gene and HLA Haplotypes
    T. F. Malivanova, E. V. Alferova, A. S. Ostashkin, T. A. Astrelina, N. N. Mazurenko
    Molecular Genetics, Microbiology and Virology.2020; 35(1): 38.     CrossRef
  • The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
    Fernando Souza-Fonseca-Guimaraes, Joseph Cursons, Nicholas D. Huntington
    Trends in Immunology.2019; 40(2): 142.     CrossRef
Fine Needle Aspiration Cytology of Thyroid Follicular Neoplasm: Cytohistologic Correlation and Accuracy
Changyoung Yoo, Hyun Joo Choi, Soyoung Im, Ji Han Jung, Kiouk Min, Chang Suk Kang, Young-Jin Suh
Korean J Pathol. 2013;47(1):61-66.   Published online February 25, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.61
  • 9,979 View
  • 62 Download
  • 15 Crossref
AbstractAbstract PDF
Background

This study evaluated the accuracy of fine needle aspiration cytology (FNAC) in cases of follicular neoplasm (FN) on the basis of histologic diagnosis, and reviewed the cytologic findings of FN according to the FNAC.

Methods

Among the 66 cases diagnosed with thyroid FN by FNAC during the 7-year period from 2003 to 2009, 36 cases that had undergone thyroid surgery were available for review. Cytologic diagnosis was compared with the histologic diagnosis of each case.

Results

Among the 36 cases with a cytologic diagnosis of thyroid FN, histologic diagnosis was as follows: 20 follicular adenomas (55.6%), 3 Hurthle cell adenomas (8.3%), 2 follicular carcinomas (5.6%), 8 nodular goiters (22.2%), 2 papillary carcinomas (5.6%), and 1 Hashimoto's thyroiditis (2.8%), resulting in a diagnostic accuracy of FNAC for thyroid FN of 69.5%.

Conclusions

This study shows that FNAC for thyroid FN is a useful primary screening method because when FN is diagnosed by FNAC, the rate of FN histologic diagnosis is relatively high, however, adequate sampling and experience is a prerequisite for this procedure.

Citations

Citations to this article as recorded by  
  • Prevalence and Predictors of Malignancy in Contralateral Thyroid Lobe in Patients Undergoing Completion Thyroidectomy
    Pradipta Kumar Parida, Siddhartha Pradhan, Chapity Preetam, Pradeep Pradhan, Dillip Kumar Samal, Saurav Sarkar
    Indian Journal of Otolaryngology and Head & Neck Surgery.2022; 74(S2): 2053.     CrossRef
  • Ultrasonographic and cytologic assessments of follicular neoplasms of the thyroid: Predictive features differentiating follicular carcinoma from follicular adenoma
    Hye Shin Ahn, Hee Sung Kim, Min Ji Hong, Paula Soares
    PLOS ONE.2022; 17(7): e0271437.     CrossRef
  • 2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
    Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
    Journal of Pathology and Translational Medicine.2020; 54(1): 64.     CrossRef
  • Preoperative diagnostic categories of fine needle aspiration cytology for histologically proven thyroid follicular adenoma and carcinoma, and Hurthle cell adenoma and carcinoma: Analysis of cause of under- or misdiagnoses
    Hee Young Na, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe, So Yeon Park, Paula Soares
    PLOS ONE.2020; 15(11): e0241597.     CrossRef
  • Core needle biopsy of thyroid nodules: outcomes and safety from a large single-center single-operator study
    Jooae Choe, Jung Hwan Baek, Hye Sun Park, Young Jun Choi, Jeong Hyun Lee
    Acta Radiologica.2018; 59(8): 924.     CrossRef
  • Cytological Features That Differentiate Follicular Neoplasm from Mimicking Lesions
    Kanghee Han, Hwa-Jeong Ha, Joon Seog Kong, Jung-Soon Kim, Jae Kyung Myung, Jae Soo Koh, Sunhoo Park, Myung-Soon Shin, Woo-Tack Song, Hye Sil Seol, Seung-Sook Lee
    Journal of Pathology and Translational Medicine.2018; 52(2): 110.     CrossRef
  • Comparison of the Diagnostic Efficacy of Ultrasound‐Guided Core Needle Biopsy With 18‐ Versus 20‐Gauge Needles for Thyroid Nodules
    Hye Shin Ahn, Mirinae Seo, Su Min Ha, Hee Sung Kim
    Journal of Ultrasound in Medicine.2018; 37(11): 2565.     CrossRef
  • Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk
    Joel Xue Yi Lim, Min En Nga, Dedrick Kok Hong Chan, Wee Boon Tan, Rajeev Parameswaran, Kee Yuan Ngiam
    Thyroid.2018; 28(4): 511.     CrossRef
  • The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation
    Galina Chernaya, Nina Mikhno, Tatiana Khabalova, Svetlana Svyatchenko, Lyudmila Mostovich, Sergey Shevchenko, Lyudmila Gulyaeva
    Surgical Oncology.2018; 27(4): 702.     CrossRef
  • The Usefulness of Immunocytochemistry of CD56 in Determining Malignancy from Indeterminate Thyroid Fine-Needle Aspiration Cytology
    Hyunseo Cha, Ju Yeon Pyo, Soon Won Hong
    Journal of Pathology and Translational Medicine.2018; 52(6): 404.     CrossRef
  • Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology
    Dong Gyu Na, Jung Hwan Baek, So Lyung Jung, Ji-hoon Kim, Jin Yong Sung, Kyu Sun Kim, Jeong Hyun Lee, Jung Hee Shin, Yoon Jung Choi, Eun Ju Ha, Hyun Kyung Lim, Soo Jin Kim, Soo Yeon Hahn, Kwang Hwi Lee, Young Jun Choi, Inyoung Youn, Young Joong Kim, Hye Sh
    Korean Journal of Radiology.2017; 18(1): 217.     CrossRef
  • Radiofrequency ablation of small follicular neoplasms: initial clinical outcomes
    Su Min Ha, Jin Yong Sung, Jung Hwan Baek, Dong Gyu Na, Ji-hoon Kim, Hyunju Yoo, Ducky Lee, Dong Whan Choi
    International Journal of Hyperthermia.2017; : 1.     CrossRef
  • A meta‐analytic review of the Bethesda System for Reporting Thyroid Cytopathology: Has the rate of malignancy in indeterminate lesions been underestimated?
    Patrizia Straccia, Esther Diana Rossi, Tommaso Bizzarro, Chiara Brunelli, Federica Cianfrini, Domenico Damiani, Guido Fadda
    Cancer Cytopathology.2015; 123(12): 713.     CrossRef
  • Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid
    Ja-Seong Bae, Seung Kyu Choi, Sora Jeon, Yourha Kim, Sohee Lee, Youn Soo Lee, Chan Kwon Jung
    International Journal of Endocrinology.2014; 2014: 1.     CrossRef
  • Diagnosis of Thyroid Follicular Neoplasm: Fine-Needle Aspiration Versus Core-Needle Biopsy
    Ra Gyoung Yoon, Jung Hwan Baek, Jeong Hyun Lee, Young Jun Choi, Min Ji Hong, Dong Eun Song, Jae Kyun Kim, Jong Ho Yoon, Won Bae Kim
    Thyroid.2014; 24(11): 1612.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine